CSNK2A1 and osteosarcoma: Therefore, our results suggest that the blocking of the CSNK2A1-SIRT6-DNA damage repair pathway might be a promising therapeutic strategy for osteosarcoma patients, especially for the poor prognostic subpopulation of patients who have tumors highly expressing CSNK2A1.